We evaluated the efficacy and safety of ertugliflozin, an SGLT2 inhibitor, in type 2 diabetes mellitus (T2DM) inadequately controlled (HbA1c, 7.0%-10.5%) with metformin monotherapy (≥1500 mg/d for ≥8 weeks).
low risk of hypoglycaemia, but with consistent genitourinary adverse events (AEs). 1, 2 Although there have been no head-to-head comparisons of efficacy or safety, the currently available SGLT2 inhibitors differ in terms of selectivity, the clinical relevance of which is presently unknown. Ertugliflozin is a highly selective SGLT2 inhibitor with 2000-fold selectivity for SGLT2 over SGLT1 in clinical development for the treatment of T2DM. 3 Phase II studies have shown that ertugliflozin improves glycaemic control and decreases body weight and blood pressure. 4, 5 Results from several phase III studies demonstrate that ertugliflozin, administered over 26 weeks, provides clinically meaningful reductions from baseline in glycated haemoglobin (HbA1c), body weight and blood pressure. [6] [7] [8] Ertugliflozin is also being developed as a fixed-dose combination (FDC) with sitagliptin and as a separate FDC with metformin.
This phase III study assessed the efficacy and safety of ertugliflozin vs placebo in adults with T2DM inadequately controlled with metformin monotherapy. Assessment of bone safety has been an area of interest in the evaluation of SGLT2 inhibitors; therefore, bone mineral density (BMD) and biomarkers of bone turnover were also evaluated.
The study population was enriched with women who were postmenopausal for ≥3 years to assess BMD changes in this population in addition to the overall cohort.
| MATERIALS AND METHODS
This 104-week, multicentre, randomized, parallel-group study com- 
| Study design
The study included a screening period (during which, if needed, background diabetes medication was adjusted to achieve a minimum 8-week metformin monotherapy stable dose [≥1500 mg/d]), followed by a 2-week, single-blind, placebo run-in period prior to randomization; a double-blind, placebo-controlled, 26-week treatment period; a double-blind, 78-week treatment extension period; and posttreatment telephone contact 14 days after the last dose of blinded study medication. Participants were counselled on appropriate dietary and lifestyle guidelines for T2DM and were asked to maintain these throughout study participation. On day 1 (randomization), each participant was assigned (1:1:1) to placebo, ertugliflozin 5 mg or ertugliflozin 15 mg using a computer-generated randomization code based on the method of random permuted blocks. Randomization was stratified into 4 groups: (1) men, (2) premenopausal women, (3) women who were perimenopausal or postmenopausal for <3 years after last menstrual period (LMP) or who underwent bilateral oophorectomy <3 years prior to screening, and (4) women who were postmenopausal ≥3 years after LMP or who underwent bilateral oophorectomy ≥3 years prior to screening. In phase A, participants received glycaemic rescue therapy with open-label glimepiride if they exceeded the following fasting plasma glucose (FPG) thresholds: >15.0 mmol/L (>270 mg/dL) after randomization through week 6, >13.3 mmol/L (>240 mg/dL) after week 6 through week 12, and >11.1 mmol/L (>200 mg/dL) after week 12 through week 26. Bone rescue therapy was to be administered to participants with a confirmed reduction from baseline in BMD of >7% at any anatomical site, together with a T-score of less than −2.5. Participants receiving glycaemic or bone rescue therapy continued to receive ertugliflozin or matching placebo.
In phase B, participants randomized to ertugliflozin continued to receive ertugliflozin; those randomized to placebo received blinded glimepiride (if not rescued during phase A).
| Participant population
The study population comprised men and women aged ≥18 years was prohibited for the entire duration of the trial. Participants who had undergone bariatric surgery were also ineligible.
| Efficacy assessments
The primary efficacy endpoint was change from baseline at week 26 in HbA1c. Pre-specified secondary efficacy endpoints were changes from baseline at week 26 in FPG, body weight, and systolic and diastolic blood pressure (SBP; DBP). Participants with HbA1c <7.0% (53 mmol/mol) at week 26 and proportions of those who received glycaemic rescue therapy were also evaluated. Body weight was measured in duplicate using a standardized digital scale. Sitting blood pressure was measured in triplicate using an automated oscillometric device.
| Safety assessments
Safety assessments included adverse event (AE) monitoring, BMD and biomarkers of bone turnover, physical examination, evaluation of vital signs (including sitting measurements and postural changes in blood pressure and pulse rate) and laboratory evaluations.
AEs of special interest identified a priori were termed "Tier 1" safety endpoints. These included symptomatic hypoglycaemia and
AEs associated with genital mycotic infection, urinary tract infection (UTI) and hypovolaemia, which were identified according to prespecified sponsor-generated customized MedDRA queries of pre- Changes in renal function were evaluated according to change from baseline in eGFR. The number and proportion of participants meeting pre-specified criteria for orthostatic change in blood pressure (ie, supine to standing position) were summarized. 
| Statistical analysis
The planned sample size of 600 participants (200 per arm) provided >99% power to detect a difference of 0.5% between each ertugliflozin dose and placebo in the change from baseline at week 26 in HbA1c, assuming a standard deviation (SD) of 1.0% based on a 2-sided test at a 5% level of significance. The sample size also provided adequate precision for comparisons of ertugliflozin vs placebo with respect to change in BMD from baseline at week 26. The half-width of the 95% confidence interval (CI) for the between-treatment difference in BMD was expected to be AE0.7% from the point estimate, which, based on BMD changes of~50% of the average change from baseline to week 80 observed for thiazolidinediones, would be precise enough to rule out any clinically relevant change. 12 Efficacy data obtained after initiation of glycaemic rescue therapy were censored (ie, treated as missing) to avoid confounding (termed "excluding glycaemic rescue"). The "excluding glycaemic rescue" approach was also the primary analysis for laboratory parameters and AEs (including hypoglycaemia), with the exception of serious AEs (SAEs), deaths,
AEs resulting in discontinuation of study medication, and measurements of postural blood pressure and pulse rate, which were assessed using the "including glycaemic rescue" approach.
| Analysis of efficacy endpoints
Efficacy analyses comprised all randomized participants who received ≥1 dose of study medication. For endpoints that used a longitudinal data analysis (LDA) model, 13 
| Analysis of safety
The safety analysis set included all participants who received ≥1 dose of study medication. For all safety endpoints of a priori interest ("Tier 1" AEs), P values and 95% CIs (with no adjustment for multiplicity)
were calculated for between-group comparisons using the Miettinen and Nurminen method. 14 The terms "significantly higher" or "significantly lower" were used to indicate P < .05. Other safety results were described as "higher" or "lower" as qualitative assessment only. The "excluding bone rescue therapy" approach was considered primary for BMD, bone biomarker and PTH analyses; however, these data were not censored after initiation of glycaemic rescue therapy. Percent changes in BMD endpoints were analysed using an LDA model as described for HbA1c.
Orthostatic changes in SBP and DBP were defined as reductions of ≥20 or ≥10 mm Hg, respectively, after 1 and 3 minutes in the standing position from the supine position (relative to the mean value from measurements taken in the supine position). Percent changes from baseline in low-and high-density lipoprotein cholesterol (LDL-C;
HDL-C) were analysed using the longitudinal method described for
HbA1c. Change from baseline in eGFR was summarized descriptively.
3 | RESULTS
| Participant disposition and baseline characteristics
In total, 621 participants were randomized ( Figure S1 ). Demographics and baseline characteristics (Table 1) were similar across treatment groups. The age range was 24 to 79 years and 15.6% of the study population was aged ≥65 years. Approximately 40% of the study population were women who were postmenopausal for ≥3 years. The median metformin dose at baseline was 2000 mg/d in all groups. At baseline, 70% of the overall population was receiving ≥1 antihypertensive medication; 60%, 22%, 21% and 24% of participants were receiving agents that act on the reninangiotensin system, beta blockers, calcium channel blockers and diuretics, respectively. The proportion of participants who discontinued study medication was 9.1%, 2.9% and 7.3% in the placebo, ertugliflozin 5-mg and ertugliflozin 15-mg groups, respectively. The most common reason in the placebo and ertugliflozin 15-mg groups was withdrawal by participant; in the ertugliflozin 5-mg group, the most common reasons were withdrawal by participant and AEs. Data are given as mean AE SD or n (%) where indicated.
a Combination blood glucose lowering agents are counted twice, under each component of the combination.
b One patient was not receiving metformin at the first screening visit but started at the second screening visit.
c n, numbers for eGFR were: placebo, 202; ertugliflozin 5 mg, 199; ertugliflozin 15 mg, 201; total, 602.
| Efficacy
Significantly greater reductions in HbA1c at week 26 were observed in both ertugliflozin groups as compared to the placebo group 
| Safety 3.3.1 | Overall AE summary
The overall incidence of AEs was similar across groups. The incidence of AEs resulting in discontinuation from study medication was low (<2%) and was similar across groups. The incidence of drug-related AEs was higher in the ertugliflozin groups compared with placebo (Table 3) , largely because of AEs related to genital mycotic infections.
The incidence of SAEs was low and was similar across groups, and none were reported as drug related by the investigator. There were no cases of ketoacidosis or deaths through week 26.
| "Tier 1" AEs/AEs of special interest
In women, the incidence of genital mycotic infections was higher in the ertugliflozin 5-mg group and significantly higher (P < .05) in the ertugliflozin 15-mg group vs placebo (Table 3 ). In men, the incidence was higher in the ertugliflozin groups vs placebo. Two participants
(1 each in the ertugliflozin 5-and 15-mg groups) discontinued study treatment because of AEs related to vulvovaginal complaints. The point estimates for the incidences of UTI and symptomatic hypoglycaemia AEs were higher in the ertugliflozin groups vs placebo.
One participant in the ertugliflozin 15-mg group discontinued study treatment because of a UTI. The incidence of hypovolaemia AEs was similar across groups ( Table 3 ). The incidence of documented hypoglycaemia was higher in the ertugliflozin groups (5 mg, 7.2%; 15 mg, 7.8%) vs placebo (4.3%). Two participants, 1 in the ertugliflozin 5-mg group and 1 in the placebo group, experienced an episode of severe hypoglycaemia that required non-medical assistance.
There was no notable change from baseline in the occurrence of events meeting orthostatic blood pressure decrease criteria in either ertugliflozin group at week 6 (SBP: 5 mg, 2.0%; 15 mg, 2.1%) or week 26 (5 mg, 4.0%; 15 mg, 4.2%), and the incidence was similar to that in the placebo group (week 6, 3.6%; week 26, 3.7%).
| BMD and bone biomarkers
Ertugliflozin had no adverse impact on BMD at week 26 (Table 4 ). An assessment by subgroup revealed results that were generally similar to those for the overall population (data not shown). Three participants, 1 in each group, had adjudication-confirmed fractures. One participant (in the ertugliflozin 5-mg group) met bone rescue criteria and received treatment. Mean serum CTX at week 26 was increased in the ertugliflozin groups in a dose-related manner, but mean P1NP and PTH levels at week 26 were similar to those at baseline (Table S1 ).
| Laboratory parameters
Small mean increases from baseline in magnesium and phosphate were initially observed at week 6 and were maintained through week 26 in both ertugliflozin groups. There was no notable change from baseline in serum calcium (Table S2 ).
In the ertugliflozin groups, decreases from baseline in eGFR (see Abbreviations: AHA, anti-hyperglycaemic agent; CI, confidence interval; cLDA, constrained longitudinal data analysis; eGFR, estimated glomerular filtration rate; HbA1c, glycated haemoglobin; LS, least-squares; SD, standard deviation.
Based on the full analysis set, excluding data after initiation of glycaemic rescue therapy.
a Based on cLDA model with fixed effects for treatment, time, prior AHA (metformin monotherapy or metformin + another AHA), baseline eGFR (continuous), menopausal status randomization stratum (men, premenopausal women, women who are perimenopausal or <3 years postmenopausal, women who are ≥3 years postmenopausal) and treatment-by-time interaction. Time was treated as a categorical variable. 
| DISCUSSION
In this study, the addition of ertugliflozin at doses of 5 and 15 mg once daily to metformin monotherapy over 26 weeks improved glycaemic control and reduced body weight, SBP and DBP without impacting BMD, but it increased the incidence of genital mycotic infections.
With both doses of ertugliflozin, decreases in HbA1c were clinically relevant and consistent with reports for other SGLT2 inhibitors. 1,2,15 Treatment with ertugliflozin also resulted in significant improvements relative to placebo in other glycaemic measures,
including FPG, and in the proportion of participants with HbA1c <7%.
In addition, treatment with ertugliflozin resulted in significantly greater reductions in body weight, SBP and DBP at week 26 relative to placebo. Although this trial was not designed to formally compare the 2 tested doses of ertugliflozin, the 15-mg dose appeared to be associated with slightly greater reductions in the primary and key secondary endpoints, with the exception of body weight loss, which was similar between the 2 doses.
The incidence of genital mycotic infections was more frequent in the ertugliflozin groups as compared to the placebo group. This is a known class effect of SGLT2 inhibitors, and these findings are consistent with the increased relative risk of genital mycotic infections reported in a meta-analysis of SGLT2 inhibitors. 16 Consistent with reports for dapagliflozin 17 and canagliflozin, 18 in the current study there was a trend for a higher incidence of UTI AEs in the ertugliflozin groups vs the placebo group, but there were no cases of complicated UTI. Symptomatic hypoglycaemia and documented hypoglycaemic events were infrequent.
Bone safety remains an area of interest with respect to SGLT2
inhibitors. The strongest evidence for bone safety involves assessment of fracture risk. However, assessment of BMD and bone biomarkers can also be informative. Potentially disparate effects on fractures are noted for SGLT2 inhibitors based on indirect comparisons of phase III results. In the canagliflozin programme, an increase in fractures was noted as early as 12 weeks. 19 While no imbalance of fractures was evident in the dapagliflozin programme, an increased incidence was observed in a study of individuals with moderate renal impairment. 20 The incidence of bone fractures in patients treated Data are shown as n (%).
a The "including rescue" approach (analysis including data obtained after the initiation of glycaemic rescue therapy) was the primary analysis for SAEs, deaths and discontinuations due to AEs. The "excluding rescue" approach (analysis excluding events occurring after glycaemic rescue medication) was the primary analysis for all other endpoints.
b Incidence significantly higher (P = .032) vs placebo group. c Episodes with a glucose level ≤ 3.9 mmol/L (70 mg/dL) with or without symptoms.
with empagliflozin was low and similar to that with placebo, 21 and was confirmed by pooled analysis. 22 In a study in patients aged 55 to 80 years, at 2 years individuals randomized to canagliflozin 100 or 300 mg had placebo-adjusted declines in BMD at the total hip of 0.9% and 1.2%, respectively, and at the lumbar spine of 0.3% and 0.7%, respectively. 23, 24 In the same study, at week 26, canagliflozin was associated with increases in CTX, a biomarker of bone resorption, of 16.2% and 23.9%, respectively, and decreases in P1NP, a biomarker of bone formation, of 5.5% and 6.8%, respectively. 25 No meaningful changes from baseline in markers of bone turnover or BMD in patients who received dapagliflozin added to metformin were reported after either 50 26 or 102 weeks. 27 However, the dapagliflozin study was small (n = 182) and did not have a population enriched with older participants. inhibitors have also been associated with transient increases in serum creatinine and decreases in eGFR. 29 In this study, there was an initial decrease in eGFR at week 6 in the ertugliflozin groups (without dose effect), but by week 26 values had returned to baseline and were similar to those with placebo.
In conclusion, for participants with T2DM who had inadequate glycaemic control with metformin monotherapy, the addition of ertugliflozin for 26 weeks provided meaningful improvements in glycaemic control and significant reductions in body weight, SBP and DBP.
Ertugliflozin was generally well tolerated; however, it was associated with a higher incidence of genital mycotic infections compared with placebo.
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